This segment focuses on the research, development, and commercialization of glycomimetic drugs for the treatment of various cancers. Key activities include the development of uproleselan, an E-selectin inhibitor, in combination with chemotherapy for acute myeloid leukemia (AML), and GMI-1359, targeting E-selectin and a chemokine receptor for cancers affecting the bone and bone marrow. Research and development efforts involve preclinical studies, clinical trials, and regulatory submissions. The company utilizes advanced glycotechnology to target specific cancer cell interactions. Patient impact is addressed by improving treatment outcomes and reducing side effects. Market positioning is based on innovative drug candidates with the potential to address unmet medical needs in oncology. Future opportunities include expanding the pipeline and exploring new indications. Regulatory and clinical aspects involve navigating FDA approval processes and conducting Phase 3 trials. Partnerships with organizations like Apollomics support clinical development and commercialization.

This segment encompasses the development of therapies for sickle cell disease and other related conditions. The primary focus is on GMI-1687, an antagonist of E-selectin, for the treatment of vaso-occlusive crisis (VOC) in sickle cell patients. Research and development activities include preclinical studies, clinical trials, and regulatory submissions. The company leverages its expertise in glycobiology to develop targeted therapies. Patient impact is addressed by reducing the frequency and severity of VOC episodes. Market positioning is based on addressing unmet needs in sickle cell disease. Future opportunities include expanding the pipeline and exploring new indications. Regulatory and clinical aspects involve navigating FDA approval processes and conducting clinical trials. Partnerships and collaborations are essential for advancing these programs.